What is HC Wainwright’s Estimate for CGTX Q1 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – HC Wainwright issued their Q1 2027 earnings estimates for Cognition Therapeutics in a research report issued to clients and investors on Friday, March 27th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS and Q4 2027 earnings at ($0.05) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04.

Other research analysts have also recently issued research reports about the company. Chardan Capital restated a “buy” rating and issued a $4.00 price target on shares of Cognition Therapeutics in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, December 29th. Finally, upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Price Performance

Shares of NASDAQ CGTX opened at $0.73 on Monday. The business has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $1.42. The stock has a market capitalization of $65.23 million, a PE ratio of -2.21 and a beta of 1.25. Cognition Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $3.83.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds have recently modified their holdings of CGTX. DAVENPORT & Co LLC grew its holdings in shares of Cognition Therapeutics by 6.8% during the fourth quarter. DAVENPORT & Co LLC now owns 2,871,836 shares of the company’s stock worth $3,877,000 after purchasing an additional 182,500 shares during the last quarter. Vanguard Group Inc. raised its holdings in Cognition Therapeutics by 105.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock valued at $3,620,000 after buying an additional 1,377,263 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Cognition Therapeutics by 11,695.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock worth $2,781,000 after buying an additional 2,042,815 shares during the period. Acadian Asset Management LLC grew its holdings in Cognition Therapeutics by 814.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after acquiring an additional 897,353 shares during the last quarter. Finally, Chescapmanager LLC grew its holdings in Cognition Therapeutics by 98.1% during the 3rd quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock worth $1,346,000 after acquiring an additional 493,770 shares during the last quarter. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics News Summary

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Q4 / year‑end 2025 results: CGTX reported adjusted results that beat consensus — EPS of ($0.02) vs. ($0.06) expected — signaling a smaller loss than anticipated. MarketBeat Earnings
• Positive Sentiment: Clinical development progress: Management reiterated advancement of zervimesine for DLB psychosis and expects a meeting with the FDA Division of Psychiatry by mid‑2026 — a concrete regulatory milestone that could define next‑step study requirements or timing. GlobeNewswire Release
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target, implying substantial upside versus current levels — a bullish endorsement that could attract longer‑term investors. Benzinga
• Neutral Sentiment: Additional disclosures and call materials: The company published its year‑end 2025 financial report and hosted a management call; full transcripts and summaries are available for investors who want details on pipeline timing, cash position, and management commentary. Earnings Call Transcript
• Negative Sentiment: Heavy selling pressure and volatility: the stock is down sharply on much higher volume than average (several million shares traded vs. an ~943k average), indicating large-scale selling or short‑term profit taking. That flow, combined with typical biotech risks (limited near‑term revenue, potential financing/dilution questions), likely overwhelmed the positive news and pushed the share price lower. MarketBeat Quote

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.